Is Truseltiq (infigratinib) still available?

According to the manufacturer (Helsinn), Truseltiq (infigratinib) will be available until [March 2023](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591034/). After this time, the medication will no longer be available in the United States.

Truseltiq

Q: What is Truseltiq (infigratinib)?

Truseltiq (infigratinib) is a capsule that's taken by mouth used to treat certain types of bile duct cancer in adults who've already tried different therapies. This medication is a type of [kinase inhibitor](https://www.goodrx.com/classes/kinase-inhibitors). It works by blocking signals in cancer cells that prevents them from growing and surviving. Truseltiq (infigratinib) was approved by the FDA based on an early clinical study showing that [23%](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma) of people who took Truseltiq (infigratinib) had a [response](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/response-rate) to the medication. This means their cancer shrunk or disappeared after the treatment. Out of the people whose cancer responded to the medication, 32% of them maintained this response for 6 months or more.

Q: Why was Truseltiq (infigratinib) discontinued?

The [manufacturer](https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-withdrawls/drugwithdrawal_truseltiq_2022-1117.pdf) (Helsinn) states that Truseltiq (infigratinib) was discontinued because researchers couldn't get enough people with bile duct cancer to participate in their clinical studies. The purpose of the studies was to confirm the medication's clinical benefit — how well the cancer responded to Truseltiq (infigratinib) and how long this response lasted. When a medication is granted an accelerated approval, the [FDA](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval) requires the manufacturer to confirm the medication's clinical benefit through studies at a later time for consideration for a traditional approval. Truseltiq (infigratinib) wasn't discontinued because of safety reasons or because the medication didn't work well. If you have questions, speak to your healthcare provider.

infigratinib

Used for Liver Cancer

Truseltiq (infigratinib) is used to treat bile duct cancer (cholangiocarcinoma) in adults. It was approved by the FDA in 2021 under accelerated approval based on its potential benefit in adults with previously treated bile duct cancer that can't be surgically removed. This medication has been discontinued and will no longer be available in the United States after March 2023.

Reviewed by:

Kristianne Hannemann, PharmD

Cydnee Ng, PharmD

Last reviewed on January 5, 2023

What is Truseltiq (infigratinib)?

What is Truseltiq (infigratinib) used for?

Bile duct cancer

Drug facts

Common Brands	Truseltiq(brand name no longer available)
Drug Class	Kinase inhibitor
Controlled Substance Classification	Not a controlled medication
Generic Status	No lower-cost generic available
Availability	Discontinued

Common Brands

Truseltiq(brand name no longer available)

Drug Class

Kinase inhibitor

Controlled Substance Classification

Not a controlled medication

Generic Status

No lower-cost generic available

Availability

Discontinued

Get your GoodRx coupon

Avg retail price

N/A

$14454.25

See prices

Common questions about Truseltiq

Truseltiq is a capsule that's taken by mouth used to treat certain types of bile duct cancer in adults who've already tried different therapies. This medication is a type of kinase inhibitor. It works by blocking signals in cancer cells that prevents them from growing and surviving. Truseltiq was approved by the FDA based on an early clinical study showing that 23% of people who took Truseltiq had a response to the medication. This means their cancer shrunk or disappeared after the treatment. Out of the people whose cancer responded to the medication, 32% of them maintained this response for 6 months or more.

According to the manufacturer (Helsinn), Truseltiq will be available until March 2023. After this time, the medication will no longer be available in the United States.

The manufacturer (Helsinn) states that Truseltiq was discontinued because researchers couldn't get enough people with bile duct cancer to participate in their clinical studies. The purpose of the studies was to confirm the medication's clinical benefit — how well the cancer responded to Truseltiq and how long this response lasted. When a medication is granted an accelerated approval, the FDA requires the manufacturer to confirm the medication's clinical benefit through studies at a later time for consideration for a traditional approval. Truseltiq wasn't discontinued because of safety reasons or because the medication didn't work well. If you have questions, speak to your healthcare provider.

Truseltiq (infigratinib) dosage

The average cost for 1 dose pack of 42 capsules of 125mg daily dose of Truseltiq (infigratinib) is $21,678.25 with a free GoodRx coupon.

Dose pack

Dosage	Quantity	Price as low as	Price per unit
42 capsules of 125mg daily dose	1 dose pack	$21,678.25	$21,678.25
21 capsules of 100mg daily dose	1 dose pack	$21,678.25	$21,678.25
63 capsules of 75mg daily dose	1 dose pack	$14,454.25	$14,454.25
42 capsules of 50mg daily dose	1 dose pack	$21,678.25	$21,678.25

Typical dosage for Truseltiq (infigratinib)

How much does Truseltiq (infigratinib) cost?

To access savings, use a GoodRx coupon and pay just a fraction of the retail price.

Truseltiq (brand)

GoodRx lowest price

$14,454.25

View prices and coupons

What are alternatives to Truseltiq (infigratinib)?

There are a number of medications that your doctor can prescribe in place of Truseltiq (infigratinib). Compare a few possible alternatives below.

Truseltiq (infigratinib)

Used for:

Bile duct cancer

$14,454.25Lowest GoodRx priceView prices

Pemazyre (pemigatinib)

Used for:

Advanced or metastatic bile duct cancer with FGFR2 genetic changes, when other treatments no longer work and surgery isn’t an option
Advanced blood cancer called myeloid/lymphoid neoplasms (MLNs) with a FGFR1 genetic change

View prices

Truseltiq (infigratinib) images

This medicine is Orange, White Dose Pack Imprinted With "Infi 100Mg".Orange, White Capsule INFI 100mg - TRUSELTIQ 125mg Daily Dose Capsule

References

National Cancer Institute. (n.d.). Response rate.

National Cancer Institute. (2022). What is bile duct cancer (cholangiocarcinoma)?

Optum, Inc. (2022). Helsinn Therapeutics – Discontinuation of Truseltiq® (infigratinib).

QED Therapeutics, Inc. (2021). Truseltiq (infigratinib) capsules, for oral use [package insert].

Subbiah, V., et al. (2023). Clinical development and management of adverse events associated with FGFR inhibitors. Cell Reports Medicine.

U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma.

U.S. Food and Drug Administration. (2023). Accelerated approval.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

What is Truseltiq (infigratinib)?

What is Truseltiq (infigratinib) used for?

Drug facts

Get your GoodRx coupon

Common questions about Truseltiq

What is Truseltiq?

Is Truseltiq still available?

Why was Truseltiq discontinued?

Truseltiq (infigratinib) dosage

Typical dosage for Truseltiq (infigratinib)

How much does Truseltiq (infigratinib) cost?

$14,454.25

What are alternatives to Truseltiq (infigratinib)?

Truseltiq (infigratinib) images

References

View All References (4)

Get your GoodRx coupon

Common questions about Truseltiq

What is Truseltiq?

Is Truseltiq still available?

Why was Truseltiq discontinued?